Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients

We retrospectively analysed the results of patients with advanced non-small-cell lung cancer treated with gefitinib to derive clinical factors predictive of response and a favourable survival outcome. Patients were treated with gefitinib 250 mg per day and re-evaluated 4–8 weeks later with repeat CT...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, S-T, Wong, E-H, Chuah, K-L, Leong, S-S, Lim, W-T, Tay, M-H, Toh, C-K, Tan, E-H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2005
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361491/
https://www.ncbi.nlm.nih.gov/pubmed/15942627
http://dx.doi.org/10.1038/sj.bjc.6602652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361491/
https://www.ncbi.nlm.nih.gov/pubmed/15942627
http://dx.doi.org/10.1038/sj.bjc.6602652

Ejemplares similares